Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC3 | Q13507 | 1/20 | 0.64 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.64 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | CRACR2A | Q9BSW2 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2092143 | 0.85 | LMNA (0.56) | TRPC3ORAI1TRPC5LMNACRACR2A | |
| SCHEMBL2094237 | 0.82 | TRPC3 (0.52) | TRPC3ORAI1TRPC5LMNACRACR2A | |
| SCHEMBL7972108 | 0.82 | LMNA (0.84) | TRPC3ORAI1TRPC5LMNACRACR2A | |
| SCHEMBL1828028 | 0.81 | PKM (0.54) | TRPC3ORAI1TRPC5LMNACRACR2A | |
| SCHEMBL7314655 | 0.80 | ORAI1 (0.81) | TRPC3ORAI1TRPC5LMNACRACR2A | |
| SCHEMBL7320623 | 0.79 | ORAI1 (0.83) | TRPC3ORAI1TRPC5LMNACRACR2A | |
| SCHEMBL12637675 | 0.79 | ORAI1 (0.83) | TRPC3ORAI1TRPC5LMNACRACR2A | |
| SCHEMBL676045 | 0.78 | ORAI1 (1.00) | TRPC3ORAI1TRPC5LMNACRACR2A | |
| SCHEMBL6621449 | 0.78 | LMNA (0.77) | TRPC3ORAI1TRPC5LMNACRACR2A | |
| SCHEMBL7325953 | 0.77 | ORAI1 (0.80) | TRPC3ORAI1TRPC5LMNACRACR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150005320-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150005320-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140107134-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140107134-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-04-17 | — | — | US | disclosed |
| EP-2319516-A1 | Compounds for treating inflammatory and autoimmune disorders | Synta Pharmaceuticals Corp. (US) | 2011-05-11 | — | — | EP | disclosed |
| WO-2005009539-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107134-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCR2, CXCL8, CCR9 | TRPC3 2002/4885ORAI1 1379/4885TRPC5 2164/4885 |
| US-20150005320-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCR2, CXCL8, CCR9 | TRPC3 2002/4885ORAI1 1379/4885TRPC5 2164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.